Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

ABLAVAR Drug Profile

« Back to Dashboard

Which patents cover Ablavar, and what substitute generic drugs are available?

Ablavar is a drug marketed by Lantheus Medcl and is included in one NDA. There is one patent protecting this drug.

This drug has forty-one patent family members in twenty-six countries.

The generic ingredient in ABLAVAR is gadofosveset trisodium. Additional details are available on the gadofosveset trisodium profile page.

Summary for Tradename: ABLAVAR

Patents:1
Applicants:1
NDAs:1
Clinical Trials: see list6
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ABLAVAR at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 2008DISCNNoNo6,676,929► SubscribeY ► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-002Dec 22, 2008DISCNNoNo6,676,929► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ABLAVAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-002Dec 22, 20087,011,815► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 20085,362,475► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 20088,017,105► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 20088,394,356► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-002Dec 22, 20088,394,356► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ABLAVAR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,011,815Diagnostic imaging contrast agents with extended blood retention► Subscribe
8,394,356Diagnostic imaging contrast agents with extended blood retention► Subscribe
8,017,105Diagnostic imaging contrast agents with extended blood retention► Subscribe
7,060,250Diagnostic imaging contrast agents with extended blood retention► Subscribe
7,229,606Diagnostic imaging contrast agents with extended blood retention► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ABLAVAR

Country Document Number Estimated Expiration
European Patent Office1716871► Subscribe
Slovenia0806968► Subscribe
Netherlands300253► Subscribe
Japan2008189683► Subscribe
Canada2539215► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ABLAVAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0806968/01Switzerland► SubscribeFORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
0253Netherlands► Subscribe300253, 20160116, EXPIRES: 20201002
C 037/2006Ireland► SubscribeSPC 037/2006: 20070528, EXPIRES: 20201002
2007003,C0806968Lithuania► SubscribePRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REGISTRATION NO/DATE: EU/1/05/313/001, 2005 10 05 EU/1/05/313/002, 2005 10 05 EU/1/05/313/003, 2005 10 05 EU/1/05/313/004, 2005 10 05 EU/1/05/313/005, 2005 10 05 EU/1/05/313/006, 2006 10 05 EU/1/05/313/007, 2005 10 05 EU/1/05/313/008, 2005 10 05 EU/1/05/313/00 2005100
C/GB07/011United Kingdom► SubscribePRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc